Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)
Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%
Immunocore cash
Cash and short-term investments held at the end of each period.
Immunocore's cash was $880.21M at Jun 30, 2026. For fiscal 2025 it was $864.15M, up 5.3% from the year before. The highest annual figure on record is $864.15M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $864.15M | +5.3% |
| FY2024 | Dec 31, 2024 | $820.38M | +85.3% |
| FY2023 | Dec 31, 2023 | $442.63M | +10.0% |
| FY2022 | Dec 31, 2022 | $402.47M | +25.3% |
| FY2021 | Dec 31, 2021 | $321.08M | +81.8% |
| FY2020 | Dec 31, 2020 | $176.66M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $880.21M | -0.3% |
| Q1 FY2026 | Mar 31, 2026 | $844.90M | +0.9% |
| Q4 FY2025 | Dec 31, 2025 | $864.15M | +5.3% |
| Q3 FY2025 | Sep 30, 2025 | $892.35M | -1.0% |
| Q2 FY2025 | Jun 30, 2025 | $882.81M | +2.7% |
| Q1 FY2025 | Mar 31, 2025 | $837.03M | +0.5% |
| Q4 FY2024 | Dec 31, 2024 | $820.38M | +85.3% |
| Q3 FY2024 | Sep 30, 2024 | $901.28M | +102.9% |
| Q2 FY2024 | Jun 30, 2024 | $859.60M | +99.0% |
| Q1 FY2024 | Mar 31, 2024 | $832.82M | +99.1% |
| Q4 FY2023 | Dec 31, 2023 | $442.63M | +10.0% |
| Q3 FY2023 | Sep 30, 2023 | $444.14M | +38.3% |
| Q2 FY2023 | Jun 30, 2023 | $432.00M | +144.5% |
| Q1 FY2023 | Mar 31, 2023 | $418.38M | – |
| Q4 FY2022 | Dec 31, 2022 | $402.47M | – |
| Q4 FY2021 | Dec 31, 2021 | $321.08M | – |
| Q4 FY2020 | Dec 31, 2020 | $176.66M | – |
See a number that looks wrong?